Navigation Links
BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
Date:4/5/2011

RALEIGH, N.C., April 5, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today completion of enrollment in its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain.

(Logo: https://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

"The completion of enrollment in our Phase 3 efficacy study marks another very important milestone in our clinical development program for BEMA Buprenorphine in the management of chronic pain," stated Dr. Andrew Finn, Executive Vice President of Product Development at BDSI.  "We are very pleased to have achieved our aggressive recruitment and enrollment goals.  This milestone keeps us on target for reporting top-line study results in the third quarter of this year and is consistent with a timeline that would allow for a New Drug Application (NDA) to be filed in the second quarter of 2012."

BDSI believes that there remains a significant unmet medical need for potent new analgesics for the treatment of chronic pain.  The company believes that buprenorphine is an attractive option for development because of its potent analgesic properties, its differentiating characteristics from other opioids and its DEA Schedule III designation, which means there is less addiction potential than Schedule II products.  In addition, BEMA Buprenorphine has the potential to be the first oral transmucosal form of buprenorphine to treat chronic pain in the U.S.  According to Wolters Kluwer, opioid analgesic sales in the U.S. are in excess of $10 billion and growing, and BDSI believes that BEMA Buprenorphine has the potential to exceed $500 million in peak annual sales.

Additional Information on Phase 3 Study Design (BUP-301)

This Phase 3 trial of BEMA Buprenorphine (referred to as BUP-301) is
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
2. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
3. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
4. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
5. TCG Lifesciences Expands Pharmaceutical, Biotechnology Research Initiatives with CAS SciFinder®
6. Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
7. Caliper Life Sciences Launches Novel COX-2 Probe to Enable Personalized Medicine Research
8. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
9. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
10. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
11. Newborn Possibilities Fund Awards Grant to Georgia Health Sciences University Foundation to Support Groundbreaking Pediatric Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015  Soligenix, ... late-stage biopharmaceutical company developing products that address unmet ... and biodefense, announced today it has completed enrollment ... Data Review Committee (DRC) earlier this year, into ... is a first-in-class innate defense regulator (IDR) and ...
(Date:8/31/2015)... STAMFORD, Conn. , Aug. 31, 2015 /PRNewswire/ ... Ltd., and Purdue Pharma L.P. announced today that they ... development and commercialization of Eisai,s clinical candidate lemborexant (development ... III clinical development for the treatment of insomnia. ... and Purdue Pharma will share the costs of lemborexant ...
(Date:8/31/2015)... 31, 2015 Research and Markets ( ... "Prescription Pain Drugs - Including Opioid, Anticonvulsant, ... Markets, Competitors and Opportunities: 2015 - 2020 Analysis ... Pain is defined as an unpleasant ... potential tissue damage. At some point, everyone experiences ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 2Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 3
... July 12 Ferring Pharmaceuticals Inc., the makers of ... Bat for the Cure charity, in an effort to "strike-out ... the organization,s Minor League Baseball initiative across the country. FIRMAGON® is ... , , ...
... (B. Braun) announced today the availability of large volume heparin infusion solutions. , ... (Logo:   http://photos.prnewswire.com/prnh/20081022/NYW008LOGO ) , ...   http://www.newscom.com/cgi-bin/prnh/20081022/NYW008LOGO ) , , , ... States Pharmacopeia (USP) standards for heparin products released by the U.S. Food and Drug Administration ...
Cached Medicine Technology:Ferring Pharmaceuticals' FIRMAGON® Named Official Sponsor of Ed Randall's Bat for the Cure 2Ferring Pharmaceuticals' FIRMAGON® Named Official Sponsor of Ed Randall's Bat for the Cure 3Ferring Pharmaceuticals' FIRMAGON® Named Official Sponsor of Ed Randall's Bat for the Cure 4B. Braun Large Volume Heparin Infusion Solutions Now Available 2B. Braun Large Volume Heparin Infusion Solutions Now Available 3
(Date:8/31/2015)... TN (PRWEB) , ... August 31, 2015 , ... ... urgent care and accessible primary care, is enhancing its existing presence in Tennessee ... in Knoxville. The location is the company’s second in Knoxville, sixteenth in Tennessee, ...
(Date:8/31/2015)... PA (PRWEB) , ... August 31, 2015 , ... ... than their peers may be at a greater risk for injury, potentially because ... behaviors, a University of Pittsburgh Graduate School of Public Health analysis discovered. ...
(Date:8/31/2015)... ... August 31, 2015 , ... Castle Dermatology Institute now ... Dr. Pedram Ghasri is a graduate of the University of California, Los Angeles. He ... studies at the University of California, Irvine Medical School. As a nationally recognized Regents ...
(Date:8/31/2015)... ... 2015 , ... The German soccer league (DFL Digital Sports) ... make website updates quicker and more flexible. The company's CMS solution FirstSpirit is ... German equivalent of the U.S. Soccer Federation) more modern, exciting and interactive for ...
(Date:8/31/2015)... ... August 31, 2015 , ... "While working as an ... effectively deliver oxygen with a lower risk of failure," explained an inventor, from ... the Adam Device." , The Adam Device offers a quick, effective and predictable ...
Breaking Medicine News(10 mins):Health News:State-of-the-Art Urgent Care Facility Opening in Knoxville 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 3Health News:Castle Dermatology Institute Now Welcomes Dr. Pedram Ghasri to the Practice 2Health News:On the Ball with FirstSpirit: German Soccer League (DFL Digital Sports) Opts for e-Spirit’s CMS 2Health News:InventHelp® Client's Invents Medical Device to Restore Respiratory Function (BGF-905) 2
... Operations of Grady Memorial Hospital, ATLANTA, Dec. 13 ... $100,000 to the Henry W. Grady Health System,Foundation. The ... Grady Memorial,Hospital, which plays a pivotal role in bringing ... AMERIGROUP Foundation is affiliated with AMERIGROUP Community Care,of Georgia, ...
... targeted treatments for leukemia, bone marrow transplants , THURSDAY, ... human blood cells has been identified by Stanford University ... treatments for blood cancers and other blood diseases. , ... the initial offspring of a blood-forming stem cell in ...
... DALLAS and LONDON, Dec. 13 U.S. ... first network focused on prevention in the,United ... it has signed a letter of intent ... preventive medicine businesses in the United Kingdom.,iHealth ...
... and 14 Walkouts at Thirteen ... Facilities, ... facilities throughout Northern California are,preparing for their second strike against the healthcare ... patient care and,patient safety. Sutter has threatened a lockout at the majority ...
... Speaker Nancy Pelosi,Majority Leader Steny Hoyer, Majority Whip James ... news conference late this afternoon in,the Capitol on the ... the bill. Below are the Speaker,s opening remarks:, ... the President,will veto the SCHIP bill. Once again, he ...
... creams, supplements and plastic surgery to look younger if they ... , A study of 297 women aged from 27 to ... with special diets, vitamins, creams, Botox or plastic surgery if ... look significantly younger. , The researchers, Professor Brett Martin ...
Cached Medicine News:Health News:AMERIGROUP Foundation Awards $100,000 to Grady Health System Foundation in Atlanta 2Health News:AMERIGROUP Foundation Awards $100,000 to Grady Health System Foundation in Atlanta 3Health News:U.S. Preventive Medicine to Expand into England with iHealth UK Ltd. 2Health News:U.S. Preventive Medicine to Expand into England with iHealth UK Ltd. 3Health News:5,000 Sutter Nurses Prepare for Second Strike Against Chain 2Health News:5,000 Sutter Nurses Prepare for Second Strike Against Chain 3Health News:Pelosi on Bush Veto of SCHIP: 'Democrats Will Not Rest Until 10 Million Children Have Access to Health Care' 2Health News:Women persist in plastic surgery treatments that are not working, research says 2
... Suture™ POLY GIA™ 75-.060 single use ... rows of LACTOMER™ absorbable copolymer staples ... the two, double rows., ,The ... use surgical stapler has application in ...
... Single Use Loading Units ... with ILA™ 75 (Single Use ... ,INDICATIONS The ILA™ 75 ... designed for use in the ...
... Reloadable Staplers and the SGIA™ Knifeless ... pediatric and thoracic surgical procedures for ... , ,The Auto Suture™ GIA™ ... Stapler have application in abdominal, gynecological, ...
... anastomotic staplers available in four sizes to ... diameter. The staplers permit tissue attachment to ... and ease of use. The instruments allow ... adjusting the height of the closed staple. ...
Medicine Products: